Optimizing the use of pneumococcal conjugate vaccine globally

Editorial

. 2013 Sep 4;310(9):911-3.

doi: 10.1001/jama.2013.228062.

Editorial

Katherine L O'Brien. JAMA. 2013.

. 2013 Sep 4;310(9):911-3.

doi: 10.1001/jama.2013.228062.

No abstract available

Comment on

Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial.
Spijkerman J, Veenhoven RH, Wijmenga-Monsuur AJ, Elberse KE, van Gageldonk PG, Knol MJ, de Melker HE, Sanders EA, Schouls LM, Berbers GA. Spijkerman J, et al. JAMA. 2013 Sep 4;310(9):930-7. doi: 10.1001/jama.2013.228052. JAMA. 2013. PMID: 24002279 Clinical Trial.

The heptavalent pneumococcal conjugate vaccine immunization project by Bangkok Metropolitan in Thai infants.
Liulak W, Thisyakorn U. Liulak W, et al. J Med Assoc Thai. 2010 Nov;93 Suppl 5:S13-5. J Med Assoc Thai. 2010. PMID: 21298831
Use of the new pneumococcal conjugate vaccine in the USA.
Baucher H. Baucher H. Arch Dis Child. 2000 Nov;83(5):396. doi: 10.1136/adc.83.5.396. Arch Dis Child. 2000. PMID: 11040145 Free PMC article. No abstract available.
Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
Zangeneh TT, Baracco G, Al-Tawfiq JA. Zangeneh TT, et al. Expert Rev Vaccines. 2011 Mar;10(3):345-53. doi: 10.1586/erv.11.1. Expert Rev Vaccines. 2011. PMID: 21434802 Review.
Pneumococcal polysaccharide-protein CRM197 conjugate vaccines, 7- or 9-valent, in the 2 + 1 schedule.
Fritzell B, Fletcher MA. Fritzell B, et al. Expert Rev Vaccines. 2011 Mar;10(3):263-90. doi: 10.1586/erv.11.11. Expert Rev Vaccines. 2011. PMID: 21434795
Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
Durando P, Faust SN, Fletcher M, Krizova P, Torres A, Welte T. Durando P, et al. Clin Microbiol Infect. 2013 Oct;19 Suppl 1:1-9. doi: 10.1111/1469-0691.12320. Clin Microbiol Infect. 2013. PMID: 24083785 Review.